PDL BioPharma, Inc. (NASDAQ:PDLI)

CAPS Rating: 4 out of 5

A biopharmaceutical company focused on discovering, developing and commercializing innovative therapies for severe or life-threatening illnesses.

Recs

0
Player Avatar stockstar69 (60.41) Submitted: 11/10/2011 12:44:19 PM : Outperform Start Price: $5.81 PDLI Score: +4.80

Decent dividend. An inovative company and competive in its field.

Featured Broker Partners


Advertisement